According to Prof Watson: “Many therapies, devices and surgical procedures have been developed to treat keratoconus, but few have been evaluated using post-market surveillance, and there is no syst in place to collect such data nationally.”Keratoconus tends to affect young adults and has a significant public health impact”.The first treatment to be evaluated via the registry is cross-linking, a relatively-new approach to halting keratoconus progression.
